Overview

• Research presented at the European Congress on Obesity (ECO25) in Malaga shows tirzepatide temporarily increases energy expenditure, while semaglutide initially reduces it.
• Tirzepatide-treated mice lost an average of 15.6 grams, compared to 8.3 grams in the semaglutide group, highlighting tirzepatide’s superior weight-loss efficacy.
• Both drugs significantly reduced food intake and enhanced fat oxidation during the initial treatment phase, as indicated by lower respiratory exchange ratios.
• Metabolic adaptations, including changes in energy expenditure and substrate utilization, reversed within two weeks of treatment cessation, leading to regained weight and increased food intake.
• Tirzepatide’s dual GLP-1/GIP receptor targeting drives unique metabolic effects independent of physical activity, offering insights for future obesity therapies focused on sustained energy expenditure.